Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Characteristics of patients in the study

From: Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer

Age, years  
   Mean (range) 48.0 (32 to 70)
Type of BRCA1 mutation  
5382insC 13
C61G 6
153delA 1
Year of initial treatment  
2000 to 2003 2
2004 to 2006 7
2007 to 2009 11
Estrogen receptor  
   Positive 5
   Negative 15
Progesterone receptor  
   Positive 3
   Negative 17
HER2 status  
   Positive 0
   Negative 20
Histology  
   Ductal 11
   Medullary 7
   Other 1
   Missing 1
Prior adjuvant chemotherapy  
Yes 13
No 7
Sites of metastases  
Liver 10
Lung 9
Bone 3
Other 11
Number of sites of metastases  
1 12
2 4
3 2
4+ 2
Prior chemotherapy for metastatic disease  
Yes 11
No 9
Line of therapy of metastatic disease  
1 9
2 2
3 8
4 1